Pharmacokinetics of oxybutynin chloride topical gel: Effects of application site, showering, sunscreen and person-to-person transference

Clinical Drug Investigation

Volumn 31, Issue 8, 2011, Pages 559-571

  Dmochowski, Roger R ^a   Newman, Diane K ^b   Sand, Peter K ^c   Rudy, Delbert C ^d   Caramelli, Kim E ^e   Thomas, Heather ^e   Hoel, Gary ^e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d Urology Associates of North Texas   (United States)

^e Watson Pharmaceuticals Inc   (United States)

Author keywords

Overactive bladder; Oxybutynin; Transdermal.

Indexed keywords

COPPERTONE; DRUG METABOLITE; N NOROXYBUTYNIN; OXYBUTYNIN; UNCLASSIFIED DRUG;

ABDOMEN; ABSENCE OF SIDE EFFECTS; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARM; ARTICLE; BIOEQUIVALENCE; CHAPPED LIP; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRY EYE; DRY LIP; DRY SKIN; GEL; HUMAN; LIP DISEASE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; SKIN; STEADY STATE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THIGH; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; AREA UNDER CURVE; CHOLINERGIC ANTAGONISTS; FEMALE; GELS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; SUNSCREENING AGENTS; THERAPEUTIC EQUIVALENCY; URINARY BLADDER, OVERACTIVE; WATER; YOUNG ADULT;

EID: 79957790613     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11588990-000000000-00000     Document Type: Article

References (21)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36 (Pubitemid 44175300)
2. Milsom I, Irwin DE. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. European Urology Supplements 2007; 6: 4-9 (Pubitemid 44821939)
3. Appell RA. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent. Drugs 2006; 66: 1361-70
4. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006 (Pubitemid 47537675)
5. DSouzaAO, SmithMJ, Miller L-A, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladdermedications in a regionalmanaged care plan. JManag Care Pharm 2008; 14: 291-301 (Pubitemid 351711980)
6. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008; 102: 774-9
7. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62
8. McCrery RJ, Appell RA. Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag 2006; 2: 19-24 (Pubitemid 43950062)
9. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515-20 (Pubitemid 18264756)
10. Hughes KM, Lang JCT, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 2009; 22: 859-69
11. Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003; 20: 103-9 (Pubitemid 36152924)
12. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001; 18: 1029-34 (Pubitemid 32799951)
13. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78: 696-702 (Pubitemid 36665899)
14. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263-70
15. Davila GW, Daugherty CA, Sanders SW, for the Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140-5 (Pubitemid 32565364)
16. Dmochowski RR, Sand PK, Zinner NR, et al., for the Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237-42 (Pubitemid 36952069)
17. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007; 99: 836-44 (Pubitemid 46439555)
18. Gelnique- (oxybutynin chloride) 10% gel prescribing information. Corona (CA): Watson Pharmaceuticals, Inc., 2009
19. Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009; 181: 1764-72
20. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry - Submission of Summary Bioequivalence Data for ANDAs. 2009 [online]. Available fromURL: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Gui dances/UCM134846.pdf [Accessed 2010 Sep 1]
21. Caramelli KE, Staskin DR, VolinnW. Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system. J Urol 2008; 179: 513-4